BioCentury | Sep 12, 2020
Management Tracks

New CEO Hirsch to guide C4 onto NASDAQ; plus Biller adds CFO title at Agios and updates from Sherlock, Lumen and more

...Diagnostics in 2000-2006.Imcyse S.A. announced Denis Bedoret has joined as CEO. He was CEO at MaSTherCell S.A. BC...
BioCentury | Feb 4, 2020
Finance

Feb. 4 Financial Quick Takes: Catalent raises $500M; venture rounds for BenchSci, Lightship, Inato

...has earmarked $330 million of the new funds to finance the deal its acquisition of MaSTherCell...
BioCentury | Feb 3, 2020
Deals

Catalent adds another foothold in new modality manufacturing via takeout of cell therapy provider MaSTherCell

...its manufacturing capacity for new modalities via the $315 million acquisition of cell therapy company MaSTherCell...
...the growing competition for manufacturing capacity in new modalities. The takeout price is nearly 16x MaSTherCell’s...
...“$1.2 Billion Catalent-Paragon Deal Latest in Race to Lock Up Gene Therapy Manufacturing” ). Buying MaSTherCell...
BioCentury | Jan 17, 2019
Emerging Company Profile

Zelluna’s solid TCR plans

...Founded: 2016 by Radforsk, Birk Venture and Inven2 University collaborators: Oslo University Hospital Corporate partners: MaSTherCell S.A....
BioCentury | Oct 19, 2018
Financial News

Iovance closes $252M follow-on for Phase II trials

...for it's late-stage European trials. MaSTherCell is a subsidiary of Orgenesis Inc. (NASDAQ: ORGS) through Masthercell...
BioCentury | Apr 7, 2017
Finance

Fast-growing evergreen

...18% stake and was the second-largest shareholder. The other two exits were cell therapy manufacturer MaSTherCell S.A....
BioCentury | Oct 26, 2016
Financial News

Fund+ closes EUR 125M fund

...women's health company Ogeda S.A. (Brussels, Belgium); cell therapy companies Promethera Biosciences S.A. (Mont-Saint-Guibert, Belgium), MaSTherCell S.A....
Items per page:
1 - 7 of 7
BioCentury | Sep 12, 2020
Management Tracks

New CEO Hirsch to guide C4 onto NASDAQ; plus Biller adds CFO title at Agios and updates from Sherlock, Lumen and more

...Diagnostics in 2000-2006.Imcyse S.A. announced Denis Bedoret has joined as CEO. He was CEO at MaSTherCell S.A. BC...
BioCentury | Feb 4, 2020
Finance

Feb. 4 Financial Quick Takes: Catalent raises $500M; venture rounds for BenchSci, Lightship, Inato

...has earmarked $330 million of the new funds to finance the deal its acquisition of MaSTherCell...
BioCentury | Feb 3, 2020
Deals

Catalent adds another foothold in new modality manufacturing via takeout of cell therapy provider MaSTherCell

...its manufacturing capacity for new modalities via the $315 million acquisition of cell therapy company MaSTherCell...
...the growing competition for manufacturing capacity in new modalities. The takeout price is nearly 16x MaSTherCell’s...
...“$1.2 Billion Catalent-Paragon Deal Latest in Race to Lock Up Gene Therapy Manufacturing” ). Buying MaSTherCell...
BioCentury | Jan 17, 2019
Emerging Company Profile

Zelluna’s solid TCR plans

...Founded: 2016 by Radforsk, Birk Venture and Inven2 University collaborators: Oslo University Hospital Corporate partners: MaSTherCell S.A....
BioCentury | Oct 19, 2018
Financial News

Iovance closes $252M follow-on for Phase II trials

...for it's late-stage European trials. MaSTherCell is a subsidiary of Orgenesis Inc. (NASDAQ: ORGS) through Masthercell...
BioCentury | Apr 7, 2017
Finance

Fast-growing evergreen

...18% stake and was the second-largest shareholder. The other two exits were cell therapy manufacturer MaSTherCell S.A....
BioCentury | Oct 26, 2016
Financial News

Fund+ closes EUR 125M fund

...women's health company Ogeda S.A. (Brussels, Belgium); cell therapy companies Promethera Biosciences S.A. (Mont-Saint-Guibert, Belgium), MaSTherCell S.A....
Items per page:
1 - 7 of 7